GlassScriptPhysician profile
Chao-Hsien Chen
NPI 1821676016
$3,791.63
in general payments reported to CMS, 2019-2025
23 companies · $452 in 2025
The $452 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $431 · 2023: $1,391 · 2024: $1,518 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $3.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.65 |
| Education | $3.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $621.63 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Genentech USA, INC. | $410.76 | 2022-2025 | Evrysdi, Activase, Ocrevus |
| Csl Behring | $385.14 | 2023-2025 | Hizentra, Kcentra |
| Argenx US, INC. | $285.95 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbvie INC. | $284.47 | 2023-2024 | Botox |
| Eisai INC. | $245.97 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $217.38 | 2022-2024 | Andexxa, Wainua |
| Acadia Pharmaceuticals INC | $214.69 | 2024-2025 | Nuplazid, Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $203.76 | 2022-2025 | Hyqvia, Gammagard |
| Biogen, INC. | $153.33 | 2022-2024 | Vumerity, Tysabri, Spinraza |
| Pfizer INC. | $108.22 | 2023 | |
| Novartis Pharmaceuticals Corporation | $104.80 | 2025 | |
| Emd Serono, INC. | $89.74 | 2022-2023 | Mavenclad |
| Genzyme Corporation | $83.16 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $79.56 | 2023 | Nuedexta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $56.65 | 2022 | |
| Springworks Therapeutics, INC. | $51.02 | 2025 | Gomekli |
| Horizon Therapeutics Plc | $44.66 | 2022 | |
| Alexion Pharmaceuticals, INC. | $41.26 | 2022-2023 | Ultomiris |
| Grifols USA, LLC | $36.20 | 2023-2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $28.31 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.01 | 2022 | |
| Amicus Therapeutics, INC. | $19.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chao-Hsien Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.